Projet MyoTreat (Horizon Europe, appel à projets 2022)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

In modern industrial societies, myopia has become an important ocular health problem of young people, due to its increased incidence and associated complications, which pose a significant risk of blindness already in the middle life span. Current treatment options have limited effects with a maximum reduction of axial elongation by about 0.4 mm over several years, equivalent to a reduction in myopia by only about 1 D. Eye growth is controlled by an interplay of different biochemical pathways, one inhibitory (stimulated by image plane in front of the retina) and one stimulatory (image plane behind the retina). A novel future strategy would be to activate the inhibitory pathways rather than inhibit the growth stimulating pathways (standard target in most studies). At present, interventions to activate growth inhibition are poorly studied. The influence of environmental factors (spectral composition of ambient light) and gene-environment interactions (specific gene variants and their interaction with key lifestyle exposures) on eye growth and refractive development will be investigated. New pharmacological targets will be identified and tested, and biomarkers established to detect the onset of myopia at an earlier stage. It will be studied how choroidal hypoxia relates to choroidal thinning and axial eye growth and how it interacts with the metabolic processes in the retina and sclera. New measurement techniques will be developed that implement artificial intelligence algorithms to improve diagnostics in myopia studies, especially in the periphery of the visual field. The proposed intersectorial and interdisciplinary "MyoTreat" project (including anatomy, physiology, pharmacology, optics, and genetics) will train PhD students in myopia research and generate and disseminate novel research results. The ultimate scientific goal is to identify new strategies for myopia therapy through hypothesis-driven translational research in various animal models as well as in humans.

Mots clés : myopia, gene environment interaction, defocus detection, pathway analysis, hypoxia, choroid

Participants :
- IntegraGen (France) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Paracelsus Medical University (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 270331.2 €
- University of South-Eastern Norway (Norvège) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 595497.6 €
- Institut norvégien de santé publique (Norvège) — Partner, associated partner, Recherche, subvention : 0.0 €
- Université Érasme de Rotterdam (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274370.4 €
- Carl Zeiss (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 521078.4 €
- Sorbonne Université (France) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 565387.2 €
- Université de Cardiff (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Trb chemedica international sa (Suisse) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université Eberhard Karl de Tübingen (Allemagne) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 521078.4 €